Sirolimus-FKBP12.6 Impairs Endothelial Barrier Function Through Protein Kinase C-α Activation and Disruption of the p120–Vascular Endothelial Cadherin Interaction | Zendy

Anwer Habib | Zendy; Vinit Karmali | Zendy; Rohini Polavarapu | Zendy; Hirokuni Akahori | Zendy; Qi Cheng | Zendy; Kim Pachura | Zendy; Frank D. Kolodgie | Zendy; Aloke V. Finn | Zendy

Open Access

Sirolimus-FKBP12.6 Impairs Endothelial Barrier Function Through Protein Kinase C-α Activation and Disruption of the p120–Vascular Endothelial Cadherin Interaction

Author(s) -

Anwer Habib,

Vinit Karmali,

Rohini Polavarapu,

Hirokuni Akahori,

Qi Cheng,

Kim Pachura,

Frank D. Kolodgie,

Aloke V. Finn

Publication year - 2013

Publication title -

arteriosclerosis thrombosis and vascular biology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.007

H-Index - 270

eISSN - 1524-4636

pISSN - 1079-5642

DOI - 10.1161/atvbaha.113.301659

Subject(s) - small interfering rna , endothelium , kinase , sirolimus , ryanodine receptor , barrier function , calcium in biology , pharmacology , microbiology and biotechnology , biology , chemistry , intracellular , endocrinology , biochemistry , transfection , gene

Sirolimus (SRL) is an immunosuppressant drug used to prevent rejection in organ transplantation and neointimal hyperplasia when delivered from drug-eluting stents. Major side effects of SRL include edema and local collection of intimal lipid deposits at drug-eluting stent sites, suggesting that SRL impairs endothelial barrier function (EBF). The aim of this study was to address the role of SRL on impaired EBF and the potential mechanisms involved.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research